agilon health inc. Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
agilon health inc. Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cash flows from operating activities: | ||||||||||||||||
| net income | -104,370,000 | 12,112,000 | -105,790,000 | -117,615,000 | -30,662,000 | -6,034,000 | -230,484,000 | 15,959,000 | -56,549,000 | -30,739,000 | -20,731,000 | 1,155,000 | -56,737,000 | -35,958,000 | -298,941,000 | -15,151,000 |
| adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||
| depreciation and amortization | 7,319,000 | 6,876,000 | 6,494,000 | 6,218,000 | 5,907,000 | 5,844,000 | 5,147,000 | 4,189,000 | 3,907,000 | 3,450,000 | 3,042,000 | 3,373,000 | 3,638,000 | 3,937,000 | 3,614,000 | 3,481,000 |
| stock-based compensation expense | 15,381,000 | 16,720,000 | 2,282,000 | 13,259,000 | 18,207,000 | 16,909,000 | 15,515,000 | 13,672,000 | 9,951,000 | 7,907,000 | 6,553,000 | 3,970,000 | 4,414,000 | 11,960,000 | 274,548,000 | 1,472,000 |
| loss (income) from equity method investments | -5,412,000 | -12,672,000 | 2,694,000 | -2,047,000 | -9,955,000 | -5,684,000 | 8,018,000 | -1,376,000 | -7,247,000 | 4,314,000 | -5,754,000 | -2,033,000 | 8,846,000 | 452,000 | ||
| distributions of earnings from equity method investments | 0 | 0 | ||||||||||||||
| adjustments on sale of assets | 0 | -14,000,000 | ||||||||||||||
| other noncash items | -878,000 | -2,229,000 | 346,000 | -365,000 | -472,000 | -1,785,000 | 764,000 | 2,941,000 | 556,000 | -2,122,000 | 245,000 | 1,766,000 | ||||
| changes in operating assets and liabilities | -91,470,000 | 16,951,000 | -46,314,000 | -30,254,000 | 2,588,000 | -16,629,000 | -33,582,000 | |||||||||
| net cash from operating activities | -35,085,000 | -31,987,000 | 16,419,000 | -7,703,000 | -18,717,000 | -47,776,000 | -61,166,000 | -60,811,000 | -49,959,000 | 2,647,000 | -60,263,000 | -23,233,000 | -48,897,000 | -19,143,000 | -39,291,000 | -40,828,000 |
| capex | -3,250,000 | -3,849,000 | -3,266,000 | -3,534,000 | -3,312,000 | -3,139,000 | -3,932,000 | -3,717,000 | -3,489,000 | -3,433,000 | -4,455,000 | -4,049,000 | -3,400,000 | -2,518,000 | -468,000 | -178,000 |
| free cash flows | -38,335,000 | -35,836,000 | 13,153,000 | -11,237,000 | -22,029,000 | -50,915,000 | -65,098,000 | -64,528,000 | -53,448,000 | -786,000 | -64,718,000 | -27,282,000 | -52,297,000 | -21,661,000 | -39,759,000 | -41,006,000 |
| cash flows from investing activities: | ||||||||||||||||
| purchase of property and equipment | -3,250,000 | -3,849,000 | -3,266,000 | -3,534,000 | -3,312,000 | -3,139,000 | -3,932,000 | -3,717,000 | -3,489,000 | -3,433,000 | -4,455,000 | -4,049,000 | -3,400,000 | -2,518,000 | -468,000 | -178,000 |
| purchase of intangible assets | -2,683,000 | -7,034,000 | -9,157,000 | -984,000 | -6,455,000 | -11,438,000 | -11,450,000 | -4,820,000 | -247,000 | -11,168,000 | -1,000,000 | -68,000 | -2,776,000 | -32,000 | -3,986,000 | |
| investment in loans receivable and other | 0 | -1,301,000 | 0 | -7,000 | -4,503,000 | -6,306,000 | -69,103,000 | -1,204,000 | ||||||||
| investments in marketable securities | -12,637,000 | -47,517,000 | 0 | 0 | -7,637,000 | -29,969,000 | -35,082,000 | -138,106,000 | ||||||||
| proceeds from maturities of marketable securities and other | 90,028,000 | 35,311,000 | 51,081,000 | 41,224,000 | 74,523,000 | |||||||||||
| net cash from investing activities | 70,458,000 | -23,089,000 | 23,673,000 | 46,563,000 | 18,217,000 | 51,438,000 | -2,203,000 | -50,814,000 | -7,970,000 | -130,938,000 | -296,611,000 | -8,869,000 | -2,603,000 | -11,565,000 | -67,264,000 | -9,074,000 |
| cash flows from financing activities: | ||||||||||||||||
| proceeds from (payments for) equity issuances | ||||||||||||||||
| repayments of long-term debt | 0 | -1,250,000 | -1,250,000 | -1,250,000 | -1,250,000 | -1,250,000 | -1,250,000 | -1,250,000 | ||||||||
| net cash from financing activities | -2,580,000 | -161,000 | -22,000 | -1,406,000 | -1,714,000 | 559,000 | -845,000 | 8,339,000 | 1,130,000 | 9,111,000 | 4,309,000 | 13,506,000 | 10,417,000 | 896,000 | 1,112,779,000 | 30,298,000 |
| net increase in cash, cash equivalents and restricted cash and equivalents | 32,793,000 | -55,237,000 | 40,070,000 | 37,454,000 | -2,214,000 | 4,221,000 | -64,214,000 | -103,286,000 | -56,799,000 | -119,180,000 | -352,565,000 | -18,596,000 | -41,083,000 | -29,812,000 | 1,006,224,000 | -19,604,000 |
| cash, cash equivalents and restricted cash and equivalents, beginning of period | 0 | 193,860,000 | 0 | 0 | 114,329,000 | 507,680,000 | 0 | 0 | 1,054,820,000 | 0 | 0 | 139,095,000 | ||||
| cash, cash equivalents and restricted cash and equivalents, end of period | 32,793,000 | 138,623,000 | 37,454,000 | -2,214,000 | 118,550,000 | 404,394,000 | -119,180,000 | -352,565,000 | 1,036,224,000 | -29,812,000 | 1,006,224,000 | 119,491,000 | ||||
| changes in operating assets and liabilities: | -38,794,000 | 92,136,000 | -3,977,000 | -63,335,000 | ||||||||||||
| proceeds from equity issuances | -161,000 | -22,000 | -156,000 | -464,000 | 1,809,000 | 9,589,000 | ||||||||||
| impairments | ||||||||||||||||
| deferred income taxes and uncertain tax positions | ||||||||||||||||
| release of indemnification assets | ||||||||||||||||
| (gain) loss on sale of assets | 0 | 4,996,000 | ||||||||||||||
| other non-cash items | ||||||||||||||||
| receivables | ||||||||||||||||
| prepaid expense and other current assets | ||||||||||||||||
| other assets | ||||||||||||||||
| medical claims and related payables | ||||||||||||||||
| accounts payable and accrued expenses | ||||||||||||||||
| other liabilities | ||||||||||||||||
| investments in loans receivable and other | ||||||||||||||||
| proceeds from maturities and sales of marketable securities and other | 30,146,000 | 28,540,000 | ||||||||||||||
| net cash paid in business combination | -773,000 | -44,367,000 | ||||||||||||||
| proceeds from sale of business and property, net of cash divested | 0 | 0 | 0 | 500,000 | 1,300,000 | 0 | ||||||||||
| common stock repurchase | 0 | |||||||||||||||
| cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of year | ||||||||||||||||
| cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of year | ||||||||||||||||
| cash, cash equivalents and restricted cash and equivalents, beginning of year | ||||||||||||||||
| cash, cash equivalents and restricted cash and equivalents from continuing operations, end of year | ||||||||||||||||
| cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of year | ||||||||||||||||
| cash, cash equivalents and restricted cash and equivalents, end of year | ||||||||||||||||
| cash, cash equivalents and restricted cash and equivalents from continuing operations, beginning of period | 0 | 0 | 114,329,000 | 0 | 0 | 1,054,820,000 | 0 | 0 | 135,178,000 | |||||||
| cash, cash equivalents and restricted cash and equivalents from discontinued operations, beginning of period | 0 | 0 | 3,917,000 | |||||||||||||
| cash, cash equivalents and restricted cash and equivalents from continuing operations, end of period | 37,454,000 | -2,214,000 | 118,550,000 | -29,812,000 | 1,006,224,000 | 119,491,000 | ||||||||||
| cash, cash equivalents and restricted cash and equivalents from discontinued operations, end of period | ||||||||||||||||
| (gain) loss on sale of assets, net and impairments | ||||||||||||||||
| funding of loans receivable and other | -8,508,000 | |||||||||||||||
| loss on debt extinguishment | 0 | 0 | 404,000 | 1,186,000 | ||||||||||||
| proceeds from initial public offering | 0 | 0 | ||||||||||||||
| proceeds from other equity issuances | 2,380,000 | 10,361,000 | ||||||||||||||
| proceeds from the issuance of long-term debt | 0 | 0 | 0 | 100,000,000 | ||||||||||||
| repayments of long-term borrowings and other | -1,252,000 | 1,000 | ||||||||||||||
| equity and debt issuance costs and other | -4,811,000 | -160,000 | ||||||||||||||
| repurchase of shares | ||||||||||||||||
| proceeds from sale of marketable securities and other | ||||||||||||||||
| proceeds from repayment of loans receivable and other | 4,096,000 | 183,000 | ||||||||||||||
| proceeds from exercise of stock options | 14,756,000 | 16,480,000 | 1,055,000 | 386,000 | 165,000 | |||||||||||
| debt issuance costs | -1,218,000 | |||||||||||||||
| distribution to noncontrolling interests | ||||||||||||||||
| computer equipment and software | ||||||||||||||||
| furniture and fixtures | ||||||||||||||||
| building | ||||||||||||||||
| proceeds from repayment of loans receivable | 35,000 | |||||||||||||||
| proceeds from sale of business, net of cash divested | -3,706,000 | |||||||||||||||
| repayments of long-term borrowings | -68,649,000 |
We provide you with 20 years of cash flow statements for agilon health inc. stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of agilon health inc. stock. Explore the full financial landscape of agilon health inc. stock with our expertly curated income statements.
The information provided in this report about agilon health inc. stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.